TGT
63
2
EQR
68
-2
PLD
56
5
TGNA
62
-2
RSG
70
2
EXPE
40
-3
V
72
4
MAC
70
3
RCL
70
-2
NUE
43
2
CF
29
2
PCAR
55
2
PHM
71
-3
MCHP
59
-4
IFF
62
9
ALLE
41
-9
MNST
61
-5
SWKS
42
2
NTRS
47
-2
LYB
46
5
TGT
63
2
EQR
68
-2
PLD
56
5
TGNA
62
-2
RSG
70
2
EXPE
40
-3
V
72
4
MAC
70
3
RCL
70
-2
NUE
43
2
CF
29
2
PCAR
55
2
PHM
71
-3
MCHP
59
-4
IFF
62
9
ALLE
41
-9
MNST
61
-5
SWKS
42
2
NTRS
47
-2
LYB
46
5
Financhill
Back

Akebia Therapeutics 10K Form

Buy
59

AKBA
Akebia Therapeutics

Last Price:
1.40
Seasonality Move:
2.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKBA News And Ratings

See the #1 stock for the next 7 days that we like better than AKBA

AKBA Financial Statistics

Sales & Book Value

Annual Sales: $194.62M
Cash Flow: $-2.31M
Price / Cash Flow: 0
Annual Sales: $-0.16
Price / Book: 0

Profitability

EPS (TTM): -0.27680
Net Income (TTM): $-51.26M
Gross Margin: $120.47M
Return on Equity: 0%
Return on Assets: -18.8%

Akebia Therapeutics Earnings Forecast

Key Akebia Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for AKBA is 61.90%.
  • The Selling, General & Administrative Expenses for AKBA have been equal to 51.50% of Gross Profit Margin.
  • The Research & Development expenses have been 32.41% of Revenue.
  • The Interest Expense is -11.62% of Operating Income.
  • The Net Earning history of AKBA is -26.68% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Akebia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKBA
CUSIP: 00972D
Website: akebia.com

Debt

Debt-to-Equity Ratio: -1.13
Current Ratio: 1.18
Quick Ratio: 0.82

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AKBA Technical Analysis vs Fundamental Analysis

Buy
59
Akebia Therapeutics (AKBA) is a Buy

Is Akebia Therapeutics a Buy or a Sell?